Drug Approval | December 21, 2024
USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Prior to taking charge at the Union Health Ministry, Jadhav planted a sapling at his residence
Subscribe To Our Newsletter & Stay Updated
